Silexion focuses on developing cutting-edge RNA-based therapies aimed at treating cancer by targeting specific genetic mutations. The company primarily serves the biopharmaceutical sector, collaborating with research institutions and healthcare providers to bring advanced treatments to market. Operating within the oncology space, Silexion's business model revolves around the research, development, and commercialization of proprietary RNA interference (RNAi) technologies. Revenue is generated through licensing agreements, partnerships, and direct sales of their therapeutic solutions. The company leverages its expertise in genetic research and drug delivery systems to create treatments that offer stronger inhibition profiles for common cancer mutations such as G12V and G12D, particularly in pancreatic cancer. Silexion's leadership team comprises experienced professionals with extensive backgrounds in pharmaceuticals, biotechnology, and strategic business planning, ensuring a robust approach to innovation and market penetration.

Keywords: RNA-based therapies, cancer treatment, genetic mutations, oncology, biopharmaceutical, RNA interference, drug delivery, pancreatic cancer, research collaboration, licensing agreements.